Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint
preservation company that creates and delivers meaningful
advancements in early intervention orthopedic care, today reported
financial results for its fourth quarter and year-ended December
31, 2020.
Fourth Quarter 2020 Financial Summary
- Revenue in the fourth quarter of
2020 increased 10% year-over-year to $32.7 million, compared to
$29.8 million, due to Joint Preservation and Restoration revenue
following the acquisitions of Parcus Medical, LLC and
Arthrosurface, Inc., in the first quarter of 2020, offset by lower
Joint Pain Management revenue as a result of the COVID
environment.
- Gross margin of 51% includes a
16-point negative impact from $5.2 million of acquisition-related
expenses.
- Net loss was $15.7 million, or
$1.10 loss per share, compared to net income of $4.1 million, or
$0.28 per diluted share, in the prior year. Net loss this quarter
included a non-cash charge for goodwill impairment offset by a
reduction in the value of contingent consideration, netting to a
charge of $11.9 million, or $0.84 per diluted share. Adjusted net
income1 for the quarter was $1.7 million, or $0.12 per diluted
share, compared to $6.3 million, or $0.43 per diluted share, in the
prior year.
- Adjusted EBITDA1 for the quarter
was $4.0 million, compared to $11.1 million for the prior
year.
- Operating cash flow during the
quarter was $2.6 million. Cash, cash equivalents and investments
totaled $98.3 million, compared to $124.8 million as of September
30, 2020. Anika repaid the remaining $25.0 million outstanding
under its credit facility in the fourth quarter of 2020.
Fiscal Year 2020 Financial Summary
- Revenue for 2020 increased 14% to
$130.5 million compared with $114.6 million, due to Joint
Preservation and Restoration revenue following the acquisitions of
Parcus Medical and Arthrosurface in the first quarter of 2020,
partly offset by lower Joint Pain Management revenue as a result of
the COVID environment.
- Gross margin of 53% includes a
13-point negative impact from $16.9 million of acquisition-related
expenses.
- Net loss of $24.0 million, or
$1.69 loss per share, compared to net income of $27.2 million, or
$1.89 per diluted share, in the prior year. Net loss in 2020
included a non-cash charge for goodwill impairment offset by a
reduction in the value of contingent consideration, netting to a
charge of $13.8 million, or $0.97 per diluted share. Adjusted net
income1 for the year was $10.1 million, or $0.71 per diluted share,
compared to $29.4 million, or $2.05 per diluted share.
- Adjusted EBITDA1 was $23.9
million, compared to $49.2 million for the prior year.
- Full year operating cash flow was
$13.1 million.
1 See description of non-GAAP financial information contained in
this release.
“I am very proud of the Anika team and their accomplishments
this year given the extraordinarily challenging market and the
complicated work environment associated with the COVID pandemic,”
said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “We
successfully ended the year with double-digit revenue growth
and positive operating cash flow, despite the COVID-related
slowdown in elective procedures that impacted our global business.
2020 was a transformative year for Anika as we integrated our two
acquisitions, Parcus Medical and Arthrosurface, and thereby
accelerated diversification of our portfolio and business,
leveraging our strength in osteoarthritis pain management as we
expand in the higher growth orthopedic spaces of regenerative
solutions, soft tissue repair and bone preserving joint
technologies. Within this greater than $8 billion global market
opportunity, we remain focused on our stated 2024 targets of
doubling revenues, expanding profitability, and creating tremendous
value for our customers, their patients, and our shareholders.”
2020 Business Highlights
- Successfully navigated the business through the COVID-19
pandemic with no significant disruptions delivering quality
products and support for our customers and their patients
- Completed transformative acquisitions of Parcus Medical and
Arthrosurface, diversifying our portfolio and expanding our market
opportunity into the >$8 billion joint preservation market.
- Strengthened the senior leadership team and board of directors
with nine new additions
- Completed the integration of the U.S. and international
commercial organizations which includes a large network of
dedicated distributors
- Launched seven new joint preservation products; received 510(k)
clearance for our WristMotion Total Arthroplasty System, which
preserves as much natural motion as possible and could help
patients avoid joint fusion
- Initiated enrollment in our pilot clinical study for Cingal in
the US (our next-generation combination viscosupplement) and
resumed enrollment in our clinical trial for Hyalofast for approval
in the US (our hyaluronic acid based cartilage regeneration
solution); we continue to sell both Cingal and Hyalofast in over 30
countries outside the United States
Fiscal 2021 Outlook
Due to the continued uncertainty in the global market associated
with the impact of the COVID-19 pandemic, the company is not
providing detailed financial guidance for 2021 at this time.
Conference Call Information
Anika’s management will hold a conference call and webcast to
discuss its financial results and business highlights today,
Thursday, March 4th at 5:00 pm ET. The conference call can be
accessed by dialing 1-855-327-6837 (toll-free domestic) or
1-631-891-4304 (international) and providing the conference ID
number 10012940. A live audio webcast will be available in the
"Investor Relations" section of Anika’s website,
www.anika.com. A slide presentation with highlights from the
conference call will be available in the Investor Relations section
of the Anika website. A replay of the webcast will be available on
Anika’s website approximately two hours after the completion of the
event.
Non-GAAP Financial Information
Non-GAAP financial measures should be considered supplemental
to, and not a substitute for, the Company’s reported financial
results prepared in accordance with GAAP. Furthermore, the
Company’s definition of non-GAAP measures may differ from similarly
titled measures used by others. Because non-GAAP financial measures
exclude the effect of items that will increase or decrease the
Company’s reported results of operations, Anika strongly encourages
investors to review the Company’s consolidated financial statements
and publicly filed reports in their entirety.
Adjusted EBITDA
Anika presents adjusted EBITDA because management uses it as a
supplemental measure in assessing the Company’s operating
performance, and the Company believes that it is helpful to
investors, securities analysts and other interested parties as a
measure of comparative operating performance from period to period.
The Company recognizes adjusted EBITDA as a commonly used measure
in determining business value and as such, uses it internally to
report results. It is also one of the performance metrics that
determines management incentive compensation.
In 2020, adjusted EBITDA is defined by the Company as GAAP net
income excluding depreciation and amortization, interest and other
income (expense), income taxes, stock-based compensation expense,
acquisition related costs, non-cash charges related to goodwill
impairment and changes in the fair value of contingent
consideration associated with the Company’s recent acquisitions as
a result of the COVID pandemic, in-process research and development
(IPR&D) write-offs, and product rationalization charges
associated with certain non-core legacy products.
Adjusted Net Income and Adjusted EPS
In addition to adjusted EBITDA, the Company is reporting its
fourth quarter 2020 results with respect to adjusted net income
(net loss) and adjusted diluted Earnings (loss) per Share (EPS)
with respect to adjusted net income. The Company believes that
adjusted net income and adjusted diluted EPS also provide
additional useful information for investors as they assess the
Company’s operating performance, as they are measures that the
Company evaluates regularly when assessing its own performance.
Adjusted net income and adjusted diluted EPS are not calculated
identically by all companies, and therefore the Company’s
measurements of adjusted net income and adjusted diluted EPS may
not be comparable to similarly titled measures reported by other
companies. Adjusted net income is defined by the Company as GAAP
net income excluding acquisition related expenses, inclusive of the
impact of purchase accounting, on a tax effected basis, as well as
certain IPR&D write-offs and the non-cash product
rationalization charges associated with certain non-core legacy
products. In the context of adjusted net income, the impact of
purchase accounting includes amortization of inventory step up and
intangible assets recorded as part of purchase accounting for
acquisition transactions. The amortized assets contribute to
revenue generation, and the amortization of such assets will recur
in future periods until such assets are fully amortized. These
assets include the estimated fair value of certain identified
assets acquired in acquisitions in 2020 and beyond, including
in-process research and development, developed technology, customer
relationships and acquired tradenames. As a result of COVID, the
Company is also specifically excluding the impacts of goodwill
impairment charges and changes in the fair value in contingent
consideration associated with the acquisition transactions, each on
a tax effected basis. Adjusted diluted EPS is defined by the
Company as GAAP diluted EPS excluding acquisition related expenses
and the impact of purchase accounting, each on a tax-adjusted per
share basis, as well as certain IPR&D write-offs and the
non-cash product rationalization charges associated with certain
non-core legacy products. Again, the Company is also specifically
excluding the impacts of goodwill impairment charges and changes in
the fair value in contingent consideration associated with the
acquisition transactions, each on a tax effected basis if
applicable. The Company is reporting this financial measure to the
Board of Directors in order to facilitate an appropriate assessment
of the Company’s performance and the impact of the COVID
pandemic.
A reconciliation of adjusted EBITDA to net income, adjusted net
income to net income and adjusted diluted EPS to diluted EPS, the
most directly comparable financial measures calculated and
presented in accordance with GAAP, is shown in the tables at the
end of this release.
About Anika Anika Therapeutics, Inc. (NASDAQ:
ANIK), is a global joint preservation company that creates and
delivers meaningful advancements in early intervention orthopedic
care. We partner with clinicians to understand what they need most
to treat their patients and we develop minimally invasive products
that restore active living for people around the world. We are
committed to leading in high opportunity spaces within orthopedics,
including osteoarthritis pain management, regenerative solutions,
soft tissue repair and bone preserving joint technologies. Anika is
headquartered in Massachusetts with operations in the United States
and Europe. For more information about Anika, please visit
www.anika.com.
Forward-Looking Statements
This press release may contain forward-looking statements,
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, concerning the Company's expectations, anticipations,
intentions, beliefs or strategies regarding the future which are
not statements of historical fact, including those statements in
the last sentence of the paragraph following the section captioned
“Fiscal Year 2020 Financial Summary” related to potential future
revenues and profitability. These statements are based upon the
current beliefs and expectations of the Company's management and
are subject to significant risks, uncertainties, and other factors.
The Company's actual results could differ materially from any
anticipated future results, performance, or achievements described
in the forward-looking statements as a result of a number of
factors including, but not limited to, (i) the Company's ability to
successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company's ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company's research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company's clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company's ability to successfully
commercialize its products, in the U.S. and abroad; (ix)
the Company's ability to provide an adequate and timely supply of
its products to its customers; and (x) the Company's ability to
achieve its growth targets. Additional factors and risks are
described in the Company's periodic reports filed with
the Securities and Exchange Commission, and they are available
on the SEC's website
at www.sec.gov. Forward-looking statements
are made based on information available to the Company on the date
of this press release, and the Company assumes no obligation to
update the information contained in this press release.
Anika Therapeutics, Inc. and Subsidiaries |
Consolidated Statements of Operations |
(in thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
|
|
|
2020 |
|
|
|
2019 |
|
|
2020 |
|
|
|
2019 |
Product revenue |
|
$ |
32,688 |
|
|
$ |
29,767 |
|
$ |
130,457 |
|
|
$ |
114,512 |
Licensing, milestone and contract revenue |
|
|
- |
|
|
|
5 |
|
|
- |
|
|
|
98 |
Total revenue |
|
|
32,688 |
|
|
|
29,772 |
|
|
130,457 |
|
|
|
114,610 |
Cost of revenue |
|
|
15,943 |
|
|
|
8,649 |
|
|
61,431 |
|
|
|
28,747 |
Gross Profit |
|
|
16,745 |
|
|
|
21,123 |
|
|
69,026 |
|
|
|
85,863 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
7,632 |
|
|
|
4,084 |
|
|
23,431 |
|
|
|
16,665 |
Selling, general and administrative |
|
|
15,179 |
|
|
|
12,237 |
|
|
60,063 |
|
|
|
34,950 |
Goodwill impairment charge |
|
|
24,376 |
|
|
|
- |
|
|
42,520 |
|
|
|
- |
Change in fair value of contingent consideration |
|
|
(12,490 |
) |
|
|
- |
|
|
(28,666 |
) |
|
|
- |
Total operating expenses |
|
|
34,697 |
|
|
|
16,321 |
|
|
97,348 |
|
|
|
51,615 |
Income (loss) from operations |
|
|
(17,952 |
) |
|
|
4,802 |
|
|
(28,322 |
) |
|
|
34,248 |
Interest and other income (expense), net |
|
|
(185 |
) |
|
|
360 |
|
|
(302 |
) |
|
|
1,873 |
Income (loss) before income taxes |
|
|
(18,137 |
) |
|
|
5,162 |
|
|
(28,624 |
) |
|
|
36,121 |
Provision (benefit) for Income taxes |
|
|
(2,480 |
) |
|
|
1,111 |
|
|
(4,642 |
) |
|
|
8,928 |
Net income (loss) |
|
$ |
(15,657 |
) |
|
$ |
4,051 |
|
$ |
(23,982 |
) |
|
$ |
27,193 |
|
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(1.10 |
) |
|
$ |
0.28 |
|
$ |
(1.69 |
) |
|
$ |
1.93 |
Diluted |
|
$ |
(1.10 |
) |
|
$ |
0.28 |
|
$ |
(1.69 |
) |
|
$ |
1.89 |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
14,275 |
|
|
|
14,280 |
|
|
14,222 |
|
|
|
14,121 |
Diluted |
|
|
14,275 |
|
|
|
14,621 |
|
|
14,222 |
|
|
|
14,374 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika Therapeutics, Inc. and Subsidiaries |
Consolidated Balance Sheets |
(in thousands, except per share data) |
(unaudited) |
|
|
|
|
|
December 31, |
|
December 31, |
ASSETS |
|
2020 |
|
|
|
2019 |
|
Current assets: |
|
|
|
Cash, cash equivalents and investments |
$ |
98,318 |
|
|
$ |
184,943 |
|
Accounts receivable, net |
|
24,102 |
|
|
|
23,079 |
|
Inventories, net |
|
46,209 |
|
|
|
21,995 |
|
Prepaid expenses and other current assets |
|
8,754 |
|
|
|
4,289 |
|
Total current assets |
|
177,383 |
|
|
|
234,306 |
|
Property and equipment, net |
|
50,613 |
|
|
|
50,783 |
|
Right-of-use assets |
|
22,619 |
|
|
|
22,864 |
|
Other long-term assets |
|
15,420 |
|
|
|
7,478 |
|
Intangible assets, net |
|
91,157 |
|
|
|
7,585 |
|
Goodwill |
|
8,413 |
|
|
|
7,694 |
|
Total assets |
$ |
365,605 |
|
|
$ |
330,710 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
8,984 |
|
|
$ |
3,832 |
|
Accrued expenses and other current liabilities |
|
14,793 |
|
|
|
12,445 |
|
Contingent consideration |
|
13,090 |
|
|
|
- |
|
Total current liabilities |
|
36,867 |
|
|
|
16,277 |
|
Other long-term liabilities |
|
1,244 |
|
|
|
357 |
|
Contingent consideration |
|
22,320 |
|
|
|
- |
|
Deferred tax liability |
|
11,895 |
|
|
|
4,331 |
|
Lease liabilities |
|
20,879 |
|
|
|
21,367 |
|
Stockholders' equity: |
|
|
|
Common stock, $0.01 par value |
|
143 |
|
|
|
143 |
|
Additional paid-in-capital |
|
55,355 |
|
|
|
48,707 |
|
Accumulated other comprehensive loss |
|
(4,542 |
) |
|
|
(5,898 |
) |
Retained earnings |
|
221,444 |
|
|
|
245,426 |
|
Total stockholders' equity |
|
272,400 |
|
|
|
288,378 |
|
Total liabilities and stockholders' equity |
$ |
365,605 |
|
|
$ |
330,710 |
|
|
|
|
|
Anika Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Net Income to Adjusted
EBITDA |
(in thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
in thousands, except per share
data |
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
Net income (loss) |
|
$ |
(15,657 |
) |
|
$ |
4,051 |
|
|
$ |
(23,982 |
) |
|
$ |
27,193 |
|
Interest and other expense (income), net |
|
|
185 |
|
|
|
(360 |
) |
|
|
302 |
|
|
|
(1,873 |
) |
(Benefit) provision for income taxes |
|
|
(2,480 |
) |
|
|
1,111 |
|
|
|
(4,642 |
) |
|
|
8,928 |
|
Depreciation and amortization |
|
|
1,714 |
|
|
|
1,532 |
|
|
|
6,844 |
|
|
|
5,991 |
|
Stock-based compensation |
|
|
1,433 |
|
|
|
1,947 |
|
|
|
5,386 |
|
|
|
6,087 |
|
Product rationalization related charges |
|
|
- |
|
|
|
- |
|
|
|
2,892 |
|
|
|
- |
|
IPR&D impairment |
|
|
1,414 |
|
|
|
|
|
1,414 |
|
|
|
- |
|
Acquisition related expenses |
|
|
- |
|
|
|
2,859 |
|
|
|
4,168 |
|
|
|
2,859 |
|
Acquisition related intangible asset amortization |
|
|
1,789 |
|
|
|
|
|
6,620 |
|
|
|
Acquisition related inventory step up |
|
|
3,697 |
|
|
|
|
|
11,082 |
|
|
|
Goodwill impairment charge |
|
|
24,376 |
|
|
|
- |
|
|
|
42,520 |
|
|
|
- |
|
Change in fair value of contingent consideration (benefit) |
|
|
(12,490 |
) |
|
|
- |
|
|
|
(28,666 |
) |
|
|
- |
|
Adjusted EBITDA |
|
$ |
3,981 |
|
|
$ |
11,140 |
|
|
$ |
23,938 |
|
|
$ |
49,185 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Net Income to Adjusted Net
Income |
(in thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
in thousands, except per share
data |
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
Net income (loss) |
|
$ |
(15,657 |
) |
|
$ |
4,051 |
|
|
$ |
(23,982 |
) |
|
$ |
27,193 |
|
Product rationalization related charges, tax effected |
|
|
- |
|
|
|
- |
|
|
|
2,376 |
|
|
|
- |
|
IPR&D impairment, tax effected |
|
|
1,414 |
|
|
|
|
|
1,414 |
|
|
|
Acquisition related expenses, tax effected |
|
|
- |
|
|
|
2,256 |
|
|
|
3,146 |
|
|
|
2,256 |
|
Acquisition related intangible asset amortization, tax
effected |
|
|
1,304 |
|
|
|
|
|
4,997 |
|
|
|
Acquisition related inventory step up |
|
|
2,696 |
|
|
|
|
|
8,365 |
|
|
|
Goodwill impairment, tax effected |
|
|
21,929 |
|
|
|
- |
|
|
|
37,702 |
|
|
|
- |
|
Change in fair value of contingent consideration, tax effected
(benefit) |
|
|
(9,999 |
) |
|
|
- |
|
|
|
(23,872 |
) |
|
|
- |
|
Adjusted net income |
|
$ |
1,687 |
|
|
$ |
6,307 |
|
|
$ |
10,146 |
|
|
$ |
29,449 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Diluted Earnings Per Share to
Adjusted Diluted Earnings Per Share |
(per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
in thousands, except per share
data |
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
Diluted earnings (loss) per share (EPS) |
|
$ |
(1.10 |
) |
|
$ |
0.28 |
|
|
$ |
(1.69 |
) |
|
$ |
1.89 |
|
Product rationalization related charges, tax effected |
|
|
- |
|
|
|
- |
|
|
|
0.17 |
|
|
|
- |
|
IPR&D impairment, tax effected |
|
|
0.10 |
|
|
|
|
|
0.10 |
|
|
|
Acquisition related expenses per share, tax effected |
|
|
- |
|
|
|
0.15 |
|
|
|
0.22 |
|
|
|
0.16 |
|
Acquisition related intangible asset amortization, tax
effected |
|
|
0.09 |
|
|
|
|
|
0.35 |
|
|
|
Acquisition related inventory step up |
|
|
0.19 |
|
|
|
|
|
0.59 |
|
|
|
Goodwill impairment, tax effected |
|
|
1.54 |
|
|
|
- |
|
|
|
2.65 |
|
|
|
- |
|
Change in fair value of contingent consideration, tax effected
(benefit) |
|
|
(0.70 |
) |
|
|
- |
|
|
|
(1.68 |
) |
|
|
- |
|
Adjusted diluted EPS |
|
$ |
0.12 |
|
|
$ |
0.43 |
|
|
$ |
0.71 |
|
|
$ |
2.05 |
|
|
|
|
|
|
|
|
|
|
Anika Therapeutics, Inc. and Subsidiaries |
Supplemental Financial Data |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by Product Family and Gross Margin |
(in thousands, except percentages) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
|
|
2020 |
|
% |
|
|
2019 |
|
% |
|
|
2020 |
|
% |
|
|
2019 |
|
% |
Joint Pain Management |
$ |
16,861 |
|
52 |
% |
|
$ |
26,403 |
|
89 |
% |
|
$ |
83,029 |
|
64 |
% |
|
$ |
103,466 |
|
90 |
% |
Joint Preservation and Restoration |
|
13,135 |
|
40 |
% |
|
|
560 |
|
2 |
% |
|
|
39,368 |
|
30 |
% |
|
|
2,070 |
|
2 |
% |
Other |
|
2,692 |
|
8 |
% |
|
|
2,804 |
|
9 |
% |
|
|
8,060 |
|
6 |
% |
|
|
8,976 |
|
8 |
% |
Product Revenue |
|
32,688 |
|
100 |
% |
|
|
29,767 |
|
100 |
% |
|
|
130,457 |
|
100 |
% |
|
|
114,512 |
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Licensing, milestone and contract revenue |
|
- |
|
- |
|
|
|
5 |
|
0 |
% |
|
|
- |
|
- |
|
|
|
98 |
|
0 |
% |
Total Revenue |
$ |
32,688 |
|
100 |
% |
|
$ |
29,772 |
|
100 |
% |
|
$ |
130,457 |
|
100 |
% |
|
$ |
114,610 |
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
$ |
16,745 |
|
|
|
$ |
21,123 |
|
|
|
$ |
69,026 |
|
|
|
$ |
85,863 |
|
|
Gross Margin |
|
51% |
|
|
|
|
71% |
|
|
|
|
53% |
|
|
|
|
75% |
|
|
For Investor Inquiries:Anika Therapeutics, Inc.Mark Namaroff,
781-457-9287Executive Director, Investor Relations and Corporate
Communicationsmnamaroff@anika.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024